NETRIS Pharma, a French clinical-stage biopharmaceutical startup, has raised an additional €7.5 million in its ongoing Series A round, bringing the total to €24.4 million. This funding, which includes an investment from the EIC Fund, will be used for clinical development and corporate growth.
NETRIS Pharma is focused on developing next-generation molecules targeting cancer resistance. The company is currently evaluating the efficacy of its anti-netrin-1 antibody candidate NP137 in combination with Atezo-bev NP137 in five clinical trials alongside chemotherapies or immunotherapies.
Strengthening the Executive Team
The executive team at NETRIS Pharma has been bolstered with the appointment of Fabien Sebille as Chief Business Officer and Gabriela Gruia to its Board of Directors. Sebille brings extensive experience in executive positions within oncology biotech companies, while Gruia, formerly of Novartis, adds significant regulatory expertise.
NETRIS Pharma’s Mission
Founded in 2008 by Patrick Mehlen and Agnes Bernet in Lyon, NETRIS Pharma aims to deliver superior clinical benefits to patients who do not respond well to anti-proliferative therapies. The company’s drugs are designed to restore cancer cell death, limit cancer cell plasticity, and alleviate resistance to current antiproliferative treatments.
Comments from Leadership
Christophe Guichard, CFO of NETRIS Pharma, highlighted the company’s progress despite challenging times for biotech fundraising. CEO Patrick Mehlen and Jean-Pierre Bizzari, Chairman of the Board, expressed confidence in the company’s future and welcomed the new board member, Gabriela Gruia, for her regulatory experience and track record.
A Step Forward in Cancer Treatment
The funding extension is a significant step in advancing its mission to develop novel therapeutic solutions for cancer patients. With its ongoing clinical trials and strengthened leadership, the company is well-positioned to make impactful advancements in cancer treatment.